Customize your search results with filters

Term Search
You can select from the dropdown list OR enter your own terms to refine the search.

Last Updated: 02/19/2023

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 1878 publications

Combination of chemotherapeutic agents and biological response modifiers (immunotherapy) in triple-negative/Her2( +) breast cancer, multiple myeloma, and non-small-cell lung cancer.

Condition: Triple-Negative/Her2( +) Breast Cancer, Multiple Myeloma, and Non-Small-Cell Lung Cancer
Journal: Journal of the Egyptian National Cancer Institute
Treatment Used: Combination Immunotherapy and Chemotherapy
Number of Patients: 0
Published: January 01, 2023

Sintilimab plus autologous NK cells as second-line treatment for advanced non-small-cell lung cancer previous treated with platinum-containing chemotherapy.

Condition: Non-Small Cell Lung Cancer (NSCLC)
Journal: Frontiers in immunology
Treatment Used: Sintilimab Plus Autologous NK Cells
Number of Patients: 20
Published: December 26, 2022

Combining PD-1 or PD-L1 inhibitors with chemotherapy is a good strategy for the treatment of extensive small cell lung cancer: A retrospective analysis of clinical studies.

Condition: Extensive-Stage Small-Cell Lung Cancer (ES-SCLC)
Journal: Frontiers in immunology
Treatment Used: Combining Programmed Cell Death (PD-1) or Programmed Cell Death Ligand 1 (PD-L1) Inhibitors with Chemotherapy vs. Chemotherapy Alone
Number of Patients: 2600
Published: December 22, 2022

Efficacy and Safety of the PD-1 Inhibitor Combined with Albumin-Bound Paclitaxel and Nedaplatin in Preoperative Neoadjuvant Therapy of Unresectable Stage III Lung Squamous Cell Carcinoma.

Condition: Stage III Lung Squamous Cell Carcinoma (SCC)
Journal: Drug design, development and therapy
Treatment Used: PD-1 Inhibitor Combined with Albumin-Bound Paclitaxel and Nedaplatin
Number of Patients: 14
Published: December 21, 2022

Efficacy and safety of icotinib in the treatment of advanced EGFR mutation-positive nonsmall cell lung cancer: A meta-analysis of randomized controlled trials.

Condition: Advanced Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Nonsmall Cell Lung Cancer (NSCLC)
Journal: Medicine
Treatment Used: Icotinib
Number of Patients: 957
Published: December 09, 2022

Reconstruction of post-resection chest wall defects in surgical treatment of invasive non-small cell lung cancer.

Condition: Invasive Non-Small Cell Lung Cancer (NSCLC)
Journal: Khirurgiia
Treatment Used: Reconstruction of Post-Resection Chest Wall Defects with Nickel-Titanium (TiNi) Implants
Number of Patients: 9
Published: December 05, 2022

Osimertinib in the Treatment of EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer: A Meta-Analysis.

Condition: EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
Journal: Pharmacology
Treatment Used: Osimertinib
Number of Patients: 1848
Published: December 05, 2022

A meta-analysis of adjuvant EGFR-TKIs for patients with EGFR mutation of resected non-small cell lung cancer.

Condition: Epidermal Growth Factor Receptor (EGFR) Mutation of Resected Non-Small Cell Lung Cancer (NSCLC)
Journal: Medicine
Treatment Used: Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitors (TKIs) vs. Adjuvant Chemotherapy (ACT)
Number of Patients: 1694
Published: December 01, 2022

Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer harboring uncommon EGFR mutations: Real-world data from Taiwan.

Condition: Non-Small Cell Lung Cancer (NSCLC)
Journal: Thoracic cancer
Treatment Used: Afatinib
Number of Patients: 230
Published: November 25, 2022

EGFR Tyrosine Kinase Inhibitor Efficacy in Older Adult Patients with Advanced EGFR-Mutated Non-Small-Cell Lung Cancer: A Meta-Analysis and Systematic Review.

Condition: Older Adult Patients with Advanced EGFR-Mutated Non-Small-Cell Lung Cancer (NSCLC)
Journal: Medicina (Kaunas, Lithuania)
Treatment Used: EGFR Tyrosine Kinase Inhibitor (TKI)
Number of Patients: 1327
Published: November 24, 2022

A phase 2 trial of chemotherapy plus pembrolizumab in patients with advanced non-small cell lung cancer previously treated with a PD-1 or PD-L1 inhibitor: Big Ten Cancer Research Consortium BTCRC-LUN15-029.

Condition: Advanced Non-Small Cell Lung Cancer (NSCLC)
Journal: Cancer
Treatment Used: Chemotherapy Plus Pembrolizumab
Number of Patients: 35
Published: November 24, 2022

Patient-reported outcomes from the randomized phase 3 CROWN study of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancer.

Condition: Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
Journal: Lung cancer (Amsterdam, Netherlands)
Treatment Used: Lorlatinib vs. Crizotinib
Number of Patients: 288
Published: November 21, 2022
Showing 1-12 of 1,878

Last Updated: 02/19/2023